Vancomycin Explained

Vancomycin is a glycopeptide antibiotic medication used to treat a number of bacterial infections.[1] It is used intravenously (injection into a vein) as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant Staphylococcus aureus.[2] Blood levels may be measured to determine the correct dose. Vancomycin is also taken orally (by mouth) as a treatment for severe Clostridium difficile colitis.[1] When taken orally it is poorly absorbed.[1]

Common side effects include pain in the area of injection and allergic reactions.[1] Occasionally, hearing loss, low blood pressure, or bone marrow suppression occur.[1] Safety in pregnancy is not clear, but no evidence of harm has been found,[1] [3] and it is likely safe for use when breastfeeding.[4] It is a type of glycopeptide antibiotic and works by blocking the construction of a cell wall.[1]

Vancomycin was approved for medical use in the United States in 1958.[5] It is on the World Health Organization's List of Essential Medicines.[6] [7] The World Health Organization classifies vancomycin as critically important for human medicine.[8] It is available as a generic medication.[9] Vancomycin is made by the soil bacterium Amycolatopsis orientalis.[1]

Medical uses

Vancomycin is indicated for the treatment of serious, life-threatening infections by Gram-positive bacteria of both aerobic and anaerobic types,[10] unresponsive to other antibiotics.[11] [12] [13]

The increasing emergence of vancomycin-resistant enterococci has resulted in the development of guidelines for use by the Centers for Disease Control Hospital Infection Control Practices Advisory Committee. These guidelines restrict use of vancomycin to these indications:[14] [15]

Spectrum of susceptibility

Vancomycin is a last resort medication for the treatment of sepsis and lower respiratory tract, skin, and bone infections caused by Gram-positive bacteria. The minimum inhibitory concentration susceptibility data for a few medically significant bacteria are:[18]

Side effects

Oral administration

Common side effects associated with oral vancomycin administration (used to treat intestinal infections) include:

Intravenous administration

Serum vancomycin levels may be monitored in an effort to reduce side effects.[19] Still, the value of such monitoring has been questioned. Peak and trough levels are usually monitored, and for research purposes, the area under the concentration curve is also sometimes used. Toxicity is best monitored by looking at trough values.[20] Immunoassays are commonly used to measure levels of vancomycin.[19]

Common adverse drug reactions (≥1% of patients) associated with intravenous (IV) vancomycin include:

Damage to the kidneys (nephrotoxicity) and to the hearing (ototoxicity) were side effects of the early impure versions of vancomycin, and these were prominent in the clinical trials conducted in the mid-1950s. Later trials using purer forms of vancomycin found nephrotoxicity is an infrequent adverse effect (0.1% to 1% of patients), but this is accentuated in the presence of aminoglycosides.[24]

Rare adverse effects associated with intravenous (IV) vancomycin (<0.1% of patients) include: anaphylaxis, toxic epidermal necrolysis, erythema multiforme, superinfection, thrombocytopenia, neutropenia, leukopenia, tinnitus, dizziness and/or ototoxicity, and DRESS syndrome.[25]

Vancomycin can induce platelet-reactive antibodies in the patient, leading to severe thrombocytopenia and bleeding with florid petechial hemorrhages, ecchymoses, and wet purpura.[26]

Historically, vancomycin has been considered a nephrotoxic and ototoxic drug, based on numerous case reports in the medical literature following initial approval by the FDA in 1958. However, as the use of vancomycin increased with the spread of MRSA beginning in the 1970s, toxicity risks were reassessed. With the removal of impurities present in earlier formulations of the drug,[5] and with the introduction of therapeutic drug monitoring, the risk for severe toxicity has been reduced.

Nephrotoxicity

The extent of nephrotoxicity for vancomycin remains controversial. In 1980s, vancomycin with a purity > 90% was available, and kidney toxicity defined by an increase in serum creatinine of at least 0.5 mg/dL, occurred in only about 5% of patients.[27] However, dosing guidelines from the 1980s until 2008 recommended vancomycin trough concentrations between 5 and 15 μg/mL.[28] Concern for treatment failures prompted recommendations for higher dosing (troughs 15 to 20 μg/mL) for serious infection, and acute kidney injury (AKI) rates attributable to the vancomycin increased.[29]

Importantly, the risk of AKI increases with co-administration of other known nephrotoxins, in particular, aminoglycosides. Furthmore, the sort of infections treated with vancomycin may also cause AKI and sepsis is the most common cause of AKI in critically ill patients. Finally, studies in humans are mainly associations studies where the cause of AKI is usually multifacotorial.

Animal studies have demonstrated that higher doses and longer duration of vancomycin exposure correlates with increased histopathologic damage and elevations in urinary biomarkers of AKI.37-38[30] Damage is most prevalent at the proximal tubule, which is further supported by urinary biomarkers, such as kidney injury molecule-1 (KIM-1), clusterin, and osteopontin (OPN),[31] and in humans, insulin-like growth factor binding protein 7 (IGFBP7) as part of the nephrocheck test.[32]

The mechanisms that underlie the pathogenesis of vancomycin nephrotoxicity are multifactorial but include interstitial nephritis, tubular injury due to oxidative stress, and cast formation.[29]

Therapeutic drug monitoring can be used during vancomycin therapy to minimize the risk of nephrotoxicity associated with excessive drug exposure. Immunoassays are commonly utilized for measuring vancomycin levels.[19]

In children, the concomitant administration of vancomycin and piperacillin/tazobactam has been associated with an elevated incidence of AKI, relative to other antibiotic regimens.[33]

Ototoxicity

Attempts to establish rates of vancomycin-induced ototoxicity are even more difficult due to the scarcity of quality evidence. The current consensus is that clearly related cases of vancomycin ototoxicity are rare.[34] [35] The association between vancomycin serum levels and ototoxicity is also uncertain. While cases of ototoxicity have been reported in patients whose vancomycin serum level exceeded 80 μg/mL,[36] cases have been reported in patients with therapeutic levels, as well. Thus, whether therapeutic drug monitoring of vancomycin for the purpose of maintaining "therapeutic" levels will prevent ototoxicity also remains unproven.[36] Still, therapeutic drug monitoring can be used during vancomycin therapy to minimize the risk of ototoxicity associated with excessive drug exposure.[19]

Interactions with other nephrotoxins

Another area of controversy and uncertainty concerns the question of whether, and if so, to what extent, vancomycin increases the toxicity of other nephrotoxins. Clinical studies have yielded variable results, but animal models indicate some increased nephrotoxic effect probably occurs when vancomycin is added to nephrotoxins such as aminoglycosides. However, a dose- or serum level-effect relationship has not been established.

Vancomycin Flushing Reaction (aka "Red man syndrome")

See also: Erythroderma. Vancomycin is recommended to be administered in a dilute solution slowly, over at least 60 min (maximum rate of 10 mg/min for doses >500 mg) due to the high incidence of pain and thrombophlebitis and to avoid an infusion reaction known as vancomycin flushing reaction. This phenomenon has been often clinically referred to as "red man syndrome". The reaction usually appears within 4 to 10 min after the commencement or soon after the completion of an infusion and is characterized by flushing and/or an erythematous rash that affects the face, neck, and upper torso, attributed to the release of histamine from mast cells. This reaction is caused by the interaction of vancomycin with MRGPRX2, a GPCR mediating IgE-independent mast cell degranulation.[37] Less frequently, hypotension and angioedema may also occur. Symptoms may be treated or prevented with antihistamines, including diphenhydramine, and are less likely to occur with slow infusion.[38] [39]

Dosing considerations

The recommended intravenous dosage in adults is 500 mg iv every 6 hours or 1000 mg every 12 hours, with modification to achieve a therapeutic range as needed. The recommended oral dosage in the treatment of antibiotic-induced pseudomembranous enterocolitis is 125 to 500 mg every 6 hours for 7 to 10 days.[40]

Dose optimization and target attainment of vancomycin in children involves adjusting the dosage of the antibiotic to maximize its effectiveness while minimizing the risk of adverse effects, specifically acute kidney injury. Dose optimization is achieved through therapeutic drug monitoring (TDM), which allows to measure vancomycin levels in the blood and tailor the dosage accordingly. TDM using area under the curve (AUC)-guided dosing, preferably with Bayesian forecasting, is recommended to ensure that the AUC0-24h/minimal inhibitory concentration (MIC) ratio is maintained above a certain threshold (400-600) associated with optimal efficacy.[41]

Routes of administration

In the United States, vancomycin is approved by the Food and Drug Administration for either intravenous or oral administration.[22]

Intravenous

Vancomycin must be given intravenously (IV) for systemic therapy, since it is poorly absorbed from the intestine. It is a large hydrophilic molecule that partitions poorly across the gastrointestinal mucosa. Due to short half-life, it is often injected twice daily.[42]

Oral

The only approved indication for oral vancomycin therapy is in the treatment of pseudomembranous colitis, where it must be given orally to reach the site of infection in the colon. Following oral administration, the fecal concentration of vancomycin is around 500 μg/mL[43] (sensitive strains of Clostridium difficile have a mean inhibitory concentration of ≤2 μg/mL[44])

Inhaled (off-label)

Inhaled vancomycin can also be used off-label,[45] via nebulizer, for the treatment of various infections of the upper and lower respiratory tract.[46] [47] [48] [49] [50]

Rectal (off-label)

Rectal administration is an off-label use of vancomycin for the treatment of Clostridium difficile infection.[22]

Therapeutic drug monitoring

Plasma level monitoring of vancomycin is necessary due to the drug's biexponential distribution, intermediate hydrophilicity, and potential for ototoxicity and nephrotoxicity, especially in populations with poor renal function and/or increased propensity to bacterial infection. Vancomycin activity is considered to be time-dependent; that is, antimicrobial activity depends on the duration that the serum drug concentration exceeds the minimum inhibitory concentration of the target organism. Thus, peak serum levels have not been shown to correlate with efficacy or toxicity; indeed, concentration monitoring is unnecessary in most cases. Circumstances in which therapeutic drug monitoring is warranted include: patients receiving concomitant aminoglycoside therapy, patients with (potentially) altered pharmacokinetic parameters, patients on haemodialysis, patients administered high-dose or prolonged treatment, and patients with impaired renal function. In such cases, trough concentrations are measured.[51] [52] [53]

Therapeutic drug monitoring is also used for dose optimization of vancomycin in treating children.[41]

Target ranges for serum vancomycin concentrations have changed over the years. Early authors suggested peak levels of 30 to 40 mg/L and trough levels of 5 to 10 mg/L,[54] but current recommendations are that peak levels need not be measured and that trough levels of 10 to 15 mg/L or 15 to 20 mg/L, depending on the nature of the infection and the specific needs of the patient, may be appropriate.[55] [56] Using measured vancomycin concentrations to calculate doses optimizes therapy in patients with augmented renal clearance.[57]

Chemistry

Vancomycin is a branched tricyclic glycosylated nonribosomal peptide produced by the Actinomycetota species Amycolatopsis orientalis (formerly designated Nocardia orientalis).

Vancomycin exhibits atropisomerism—it has multiple chemically distinct rotamers owing to the rotational restriction of some of the bonds. The form present in the drug is the thermodynamically more stable conformer.

Biosynthesis

Vancomycin is made by the soil bacterium Amycolatopsis orientalis.[1] Vancomycin biosynthesis occurs primarily via three nonribosomal protein syntheses (NRPSs) VpsA, VpsB, and VpsC.[58] The enzymes determine the amino acid sequence during its assembly through its 7 modules. Before vancomycin is assembled through NRPS, the non-proteinogenic amino acids are first synthesized. L-tyrosine is modified to become the β-hydroxytyrosine (β-HT) and 4-hydroxyphenylglycine (4-Hpg) residues. 3,5 dihydroxyphenylglycine ring (3,5-DPG) is derived from acetate.[59]

Nonribosomal peptide synthesis occurs through distinct modules that can load and extend the protein by one amino acid per module through the amide bond formation at the contact sites of the activating domains.[60] Each module typically consists of an adenylation (A) domain, a peptidyl carrier protein (PCP) domain, and a condensation (C) domain. In the A domain, the specific amino acid is activated by converting into an aminoacyl adenylate enzyme complex attached to a 4'phosphopantetheine cofactor by thioesterification.[61] [62] The complex is then transferred to the PCP domain with the expulsion of AMP. The PCP domain uses the attached 4'-phosphopantethein prosthetic group to load the growing peptide chain and their precursors.[63] The organization of the modules necessary to biosynthesize Vancomycin is shown in Figure 1. In the biosynthesis of Vancomycin, additional modification domains are present, such as the epimerization (E) domain, which isomerizes the amino acid from one stereochemistry to another, and a thioesterase domain (TE) is used as a catalyst for cyclization and releases of the molecule via a thioesterase scission.

A set of NRPS enzymes (peptide synthase VpsA, VpsB, and VpsC) are responsible for assembling the heptapeptide. (Figure 2).[60] VpsA codes for modules 1, 2, and 3. VpsB codes for modules 4, 5, and 6, and VpsC codes for module 7. The vancomycin aglycone contains 4 D-amino acids, although the NRPSs only contain 3 epimerization domains. The origin of D-Leu at residue 1 is not known. The three peptide syntheses are located at the start of the region of the bacterial genome linked with antibiotic biosynthesis, and span 27 kb.[60]

β-hydroxytyrosine (β-HT) is synthesized prior to incorporation into the heptapeptide backbone. L-tyrosine is activated and loaded on the NRPS VpsD, hydroxylated by OxyD, and released by the thioesterase Vhp.[64] The timing of the chlorination by halogenase VhaA during biosynthesis is currently undetermined, but is proposed to occur before the complete assembly of the heptapeptide.[65]

After the linear heptapeptide molecule is synthesized, vancomycin has to undergo further modifications, such as oxidative cross-linking and glycosylation, in trans by distinct enzymes, referred to as tailoring enzymes, to become biologically active (Figure 3). To convert the linear heptapeptide to cross-linked, glycosylated vancomycin, six enzymes, are required. The enzymes OxyA, OxyB, OxyC, and OxyD are cytochrome P450 enzymes. OxyB catalyzes oxidative cross-linking between residues 4 and 6, OxyA between residues 2 and 4, and OxyC between residues 5 and 7. This cross-linking occurs while the heptapeptide is covalently bound to the PCP domain of the 7th NRPS module. These P450s are recruited by the X domain present in the 7th NRPS module, which is unique to glycopeptide antibiotic biosynthesis.[66] The cross-linked heptapeptide is then released by the action of the TE domain, and methyltransferase Vmt then N-methylates the terminal leucine residue. GtfE then joins D-glucose to the phenolic oxygen of residue 4, followed by the addition of vancosamine catalyzed by GtfD.

Some of the glycosyltransferases capable of glycosylating vancomycin and related nonribosomal peptides display notable permissivity and have been employed for generating libraries of differentially glycosylated analogs through a process known as glycorandomization.[67] [68] [69]

Total synthesis

Both the vancomycin aglycone[70] [71] and the complete vancomycin molecule[72] have been targets successfully reached by total synthesis. The target was first achieved by David Evans in October 1998, KC Nicolaou in December 1998, Dale Boger in 1999, and more selectively synthesized again by Dale Boger in 2020.[73] [74]

Mechanism of action

Vancomycin targets bacterial cell wall synthesis by binding to the basic building block of the bacterial cell wall of Gram-positive bacteria, whether it is of aerobic or anaerobic type.[10] Specifically, vancomycin forms hydrogen bonds with the D-alanyl-D-alanine (D-Ala-D-Ala) peptide motif of the peptidoglycan precursor, a crucial component of the bacterial cell wall.[11]

Peptidoglycan is a polymer that provides structural support to the bacterial cell wall. The peptidoglycan precursor is synthesized in the cytoplasm and then transported across the cytoplasmic membrane to the periplasmic space, where it is assembled into the cell wall. The assembly process involves two enzymatic activities: transglycosylation and transpeptidation. Transglycosylation involves the polymerization of the peptidoglycan precursor into long chains, while transpeptidation involves the cross-linking of these chains to form a three-dimensional mesh-like structure.[11]

Vancomycin inhibits bacterial cell wall synthesis by binding to the D-Ala-D-Ala peptide motif of the peptidoglycan precursor, thereby preventing its processing by the transglycosylase; as such vancomycin disrupts the transglycosylation activity of the cell wall synthesis process. The disruption leads to an incomplete and corrupted cell wall, which makes the replicating bacteria vulnerable to external forces such as osmotic pressure, so that the bacteria cannot survive and are eliminated by the immune system.[11]

Gram-negative bacteria are insensitive to vancomycin due to their different cell wall morphology. The outer membrane of Gram-negative bacteria contains lipopolysaccharide, which acts as a barrier to vancomycin penetration. That is why vancomycin is mainly used to treat infections caused by Gram-positive bacteria[11] (except some nongonococcal species of Neisseria).[75] [76]

The large hydrophilic molecule of vancomycin is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. Under normal circumstances, this is a five-point interaction. This binding of vancomycin to the D-Ala-D-Ala prevents cell wall synthesis of the long polymers of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) that form the backbone strands of the bacterial cell wall, and prevents the backbone polymers from cross-linking with each other.[77]

Plant tissue culture

Vancomycin is one of the few antibiotics used in plant tissue culture to eliminate Gram-positive bacterial infection. It has relatively low toxicity to plants.[78] [79]

Antibiotic resistance

Intrinsic resistance

A few Gram-positive bacteria are intrinsically resistant to vancomycin: Leuconostoc and Pediococcus species, but these organisms rarely cause diseases in humans.[80] Most Lactobacillus species are also intrinsically resistant to vancomycin,[80] with the exception of L. acidophilus and L. delbrueckii, which are sensitive.[81] Other Gram-positive bacteria with intrinsic resistance to vancomycin include Erysipelothrix rhusiopathiae, Weissella confusa, and Clostridium innocuum.[82] [83] [84]

Most Gram-negative bacteria are intrinsically resistant to vancomycin because their outer membranes are impermeable to large glycopeptide molecules[85] (with the exception of some non-gonococcal Neisseria species).[86]

Acquired resistance

Evolution of microbial resistance to vancomycin is a growing problem, in particular, within healthcare facilities such as hospitals. While newer alternatives to vancomycin exist, such as linezolid (2000) and daptomycin (2003), the widespread use of vancomycin makes resistance to the drug a significant worry, especially for individual patients if resistant infections are not quickly identified and the patient continues the ineffective treatment. Vancomycin-resistant Enterococcus emerged in 1986.[87] Vancomycin resistance evolved in more common pathogenic organisms during the 1990s and 2000s, including vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA).[88] [89] Agricultural use of avoparcin, another similar glycopeptide antibiotic, may have contributed to the evolution of vancomycin-resistant organisms.[90] [91] [92] [93]

One mechanism of resistance to vancomycin involves the alteration to the terminal amino acid residues of the NAM/NAG-peptide subunits, under normal conditions, D-alanyl-D-alanine, to which vancomycin binds. The D-alanyl-D-lactate variation results in the loss of one hydrogen-bonding interaction (4, as opposed to 5 for D-alanyl-D-alanine) possible between vancomycin and the peptide. This loss of just one point of interaction results in a 1000-fold decrease in affinity. The D-alanyl-D-serine variation causes a six-fold loss of affinity between vancomycin and the peptide, likely due to steric hindrance.[94]

In enterococci, this modification appears to be due to the expression of an enzyme that alters the terminal residue. Three main resistance variants have been characterised to date among resistant Enterococcus faecium and E. faecalis populations:

Variant of vancomycin has been tested that binds to the resistant D-lactic acid variation in vancomycin-resistant bacterial cell walls, and also binds well to the original target (vancomycin-susceptible bacteria).[95] [96]

"Re-gained" vancomycin

In 2020 a team at the University Hospital Heidelberg (Germany) re-gained the antibacterial power of vancomycin by modifying the molecule with a cationic oligopeptide. The oligopeptide consists of six arginin units in Position VN. In comparison to the unmodified vancomycin the activity against vancomycin-resistant bacteria could be enhanced by a factor of 1,000.[97] [98] This pharmacon is still in preclinical development.

History

Vancomycin was first isolated in 1953, by Edmund Kornfeld (working at Eli Lilly) from a bacteria in a soil sample collected from the interior jungles of Borneo by a missionary, William M. Bouw (1918–2006).[99] The organism that produced it was eventually named Amycolatopsis orientalis.[5] The original indication for vancomycin was for the treatment of penicillin-resistant Staphylococcus aureus.[5] [100]

The compound was initially called compound 05865, but was eventually given the generic name vancomycin, derived from the term "vanquish".[5] One advantage that was quickly apparent was that staphylococci did not develop significant resistance, despite serial passage in culture media containing vancomycin. The rapid development of penicillin resistance by staphylococci led to its being fast-tracked for approval by the Food and Drug Administration. In 1958, Eli Lilly first marketed vancomycin hydrochloride under the trade name Vancocin.[100]

Vancomycin never became the first-line treatment for S. aureus for several reasons:

  1. It possesses poor oral bioavailability, so must be given intravenously for most infections.
  2. β-Lactamase-resistant semisynthetic penicillins such as methicillin (and its successors, nafcillin and cloxacillin) were subsequently developed, which have better activity against non-MRSA staphylococci.
  3. Early trials used early, impure forms of the drug ("Mississippi mud"), which were found to be toxic to the inner ear and to the kidneys;[101] these findings led to vancomycin's being relegated to the position of a drug of last resort.[100]

In 2004, Eli Lilly licensed Vancocin to ViroPharma in the U.S., Flynn Pharma in the UK, and Aspen Pharmacare in Australia. The patent had expired in the early 1980s, and the FDA authorized the sale of several generic versions in the US, including from manufacturers Bioniche Pharma, Baxter Healthcare, Sandoz, Akorn-Strides, and Hospira.[102]

Research

The combination of vancomycin powder and povidone-iodine lavage may reduce the risk of periprosthetic joint infection in hip and knee arthroplasties. [103]

Notes and References

  1. Web site: Vancocin. The American Society of Health-System Pharmacists. 4 September 2015. live. https://web.archive.org/web/20150906002445/http://www.drugs.com/monograph/vancocin.html. 6 September 2015.
  2. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF . Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary . Clinical Infectious Diseases . 52 . 3 . 285–92 . February 2011 . 21217178 . 10.1093/cid/cir034 . free .
  3. Web site: Prescribing medicines in pregnancy database. Australian Government. September 2015. live. https://web.archive.org/web/20140408040902/http://www.tga.gov.au/hp/medicines-pregnancy.htm#.U1Yw8Bc3tqw. 8 April 2014.
  4. Web site: Vancomycin use while Breastfeeding. 5 September 2015. live. https://web.archive.org/web/20150907040510/http://www.drugs.com/breastfeeding/vancomycin.html. 7 September 2015.
  5. Levine DP . Vancomycin: a history . Clinical Infectious Diseases . 42 . Suppl 1 . S5–12 . January 2006 . 16323120 . 10.1086/491709 . free .
  6. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 21st list 2019 . 2019 . 10665/325771 . World Health Organization . World Health Organization . Geneva . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO . free .
  7. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 22nd list (2021) . 2021 . 10665/345533 . World Health Organization . World Health Organization . Geneva . WHO/MHP/HPS/EML/2021.02 . free .
  8. Book: ((World Health Organization)) . 2019 . Critically important antimicrobials for human medicine . 6th revision . World Health Organization . World Health Organization . Geneva . 10665/312266 . 978-92-4-151552-8 . free .
  9. Book: Hamilton R . Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. 2015. Jones & Bartlett Learning. 978-1-284-05756-0. 91.
  10. Book: 10.1016/B978-0-444-63749-9.00008-6 . From Natural Products to Drugs . Studies in Natural Products Chemistry . 2016 . Biondi S, Chugunova E, Panunzio M . 50 . 249–297 . 978-0-444-63749-9 .
  11. Mühlberg E, Umstätter F, Kleist C, Domhan C, Mier W, Uhl P . Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteria . Can J Microbiol . 66 . 1 . 11–16 . January 2020 . 31545906 . 10.1139/cjm-2019-0309. 1807/96894 . 202745549 . free .
  12. Stogios PJ, Savchenko A . Molecular mechanisms of vancomycin resistance . Protein Sci . 29 . 3 . 654–669 . March 2020 . 31899563 . 7020976 . 10.1002/pro.3819 .
  13. Bruniera FR, Ferreira FM, Saviolli LR, Bacci MR, Feder D, da Luz Gonçalves Pedreira M, Sorgini Peterlini MA, Azzalis LA, Campos Junqueira VB, Fonseca FL . The use of vancomycin with its therapeutic and adverse effects: a review . Eur Rev Med Pharmacol Sci . 19 . 4 . 694–700 . February 2015 . 25753888 .
  14. Book: Rossi S . . Adelaide . Australian Medicines Handbook . 2006 . 0-9757919-2-3 .
  15. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC) . MMWR. Recommendations and Reports . 44 . RR-12 . 1–13 . September 1995 . 7565541 . live . https://web.archive.org/web/20060923012326/http://wonder.cdc.gov/wonder/prevguid/m0039349/m0039349.asp . 23 September 2006 .
  16. Lifshitz T, Lapid-Gortzak R, Finkelman Y, Klemperer I . Vancomycin and ceftazidime incompatibility upon intravitreal injection . The British Journal of Ophthalmology . 84 . 1 . 117–8 . January 2000 . 10691328 . 1723217 . 10.1136/bjo.84.1.117a .
  17. Web site: Office of the Commissioner. Safety Alerts for Human Medical Products - Intraocular Injections of a Compounded Triamcinolone, Moxifloxacin, and Vancomycin (TMV) Formulation: FDA Statement - Case of Hemorrhagic Occlusive Retinal Vasculitis. www.fda.gov. 6 October 2017. en. 3 October 2017. https://web.archive.org/web/20171003211204/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm578743.htm. live.
  18. Web site: Vancomycin (Vancocyn, Lyphocin) | the Antimicrobial Index Knowledgebase - TOKU-E . 26 February 2014 . live . https://web.archive.org/web/20140227000847/http://antibiotics.toku-e.com/antimicrobial_1182_1.html . 27 February 2014 .
  19. Cafaro A, Barco S, Pigliasco F, Russo C, Mariani M, Mesini A, Saffioti C, Castagnola E, Cangemi G . Therapeutic drug monitoring of glycopeptide antimicrobials: An overview of liquid chromatography-tandem mass spectrometry methods . J Mass Spectrom Adv Clin Lab . 31 . 33–39 . January 2024 . 38304144 . 10.1016/j.jmsacl.2023.12.003 . 10831154 .
  20. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL . Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients . Clinical Infectious Diseases . 49 . 4 . 507–14 . August 2009 . 19586413 . 10.1086/600884 . free .
  21. Web site: Vancomycin Injection: MedlinePlus Drug Information. medlineplus.gov. 19 July 2023. 19 July 2023. https://web.archive.org/web/20230719123049/https://medlineplus.gov/druginfo/meds/a601167.html. live.
  22. Book: https://www.ncbi.nlm.nih.gov/books/NBK459263/ . 29083794 . 2023 . Patel S, Preuss CV, Bernice F . Vancomycin . StatPearls [Internet] . Treasure Island (FL) . StatPearls Publishing . 19 July 2023 . 11 April 2023 . https://web.archive.org/web/20230411041350/https://www.ncbi.nlm.nih.gov/books/NBK459263/ . live .
  23. Leroy S, Piquet P, Chidiac C, Ferry T . Extensive thrombophlebitis with gas associated with continuous infusion of vancomycin through a central venous catheter . BMJ Case Rep . 2012 . bcr2012006347. May 2012 . 22669879 . 4543351 . 10.1136/bcr-2012-006347.
  24. Farber BF, Moellering RC . Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981 . Antimicrobial Agents and Chemotherapy . 23 . 1 . 138–41 . January 1983 . 6219616 . 184631 . 10.1128/AAC.23.1.138 .
  25. Blumenthal KG, Patil SU, Long AA . The importance of vancomycin in drug rash with eosinophilia and systemic symptoms (DRESS) syndrome . Allergy and Asthma Proceedings . 33 . 2 . 165–71 . 1 April 2012 . 22525393 . 10.2500/aap.2012.33.3498 .
  26. Von Drygalski A, Curtis BR, Bougie DW, McFarland JG, Ahl S, Limbu I, Baker KR, Aster RH . Vancomycin-induced immune thrombocytopenia . The New England Journal of Medicine . 356 . 9 . 904–10 . March 2007 . 17329697 . 10.1056/NEJMoa065066 . free .
  27. Farber BF, Moellering RC Jr . Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. . Antimicrob Agents Chemother . 1 . 138–41 . 1983 . 1 . 10.1128/AAC.23.1.138 . 6219616 . 184631 .
  28. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. . Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. . Clin Infect Dis . 49 . 325–7 . 2009 . 3 . 10.1086/600877 . 19569969 . 32585259 . free .
  29. Pais GM, Liu J, Zepcan S, Avedissian SN, Rhodes NJ, Downes KJ, Moorthy GS, Scheetz MH . Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention . Pharmacotherapy . 40 . 5 . 438–454 . 2020 . 10.1002/phar.2388 . 32239518 . 7331087 .
  30. Fuchs TC, Frick K, Emde B, Czasch S, von Landenberg F, Hewitt P . Evaluation of novel acute urinary rat kidney toxicity biomarker for subacute toxicity studies in preclinical trials. . Toxicol Pathol . 40 . 1031–48 . 2012 . 7 . 10.1177/0192623312444618 . 22581810 . 45358082 .
  31. Pais GM, Avedissian SN, ODonnell JN et al. . Comparative performance of urinary biomarkers for vancomycin-induced kidney injury according to timeline of injury. . Antimicrob Agents Chemother . 2019 . 63 . 7 . e00079–19 . 10.1128/AAC.00079-19 . 30988153 . 6591602 .
  32. Ostermann M, McCullough PA, Forni LG . Kinetics of Urinary Cell Cycle Arrest Markers for Acute Kidney Injury Following Exposure to Potential Renal Insults. . Crit Care Med . 46 . 3 . 375–383 . 2018 . 10.1097/CCM.0000000000002847 . 29189343 . 5821475 .
  33. Zhang M, Huang L, Zhu Y, Zeng L, Jia ZJ, Cheng G, Li H, Zhang L . Epidemiology of Vancomycin in Combination With Piperacillin/Tazobactam-Associated Acute Kidney Injury in Children: A Systematic Review and Meta-analysis . Ann Pharmacother . 10600280231220379 . January 2024 . 38279799 . 10.1177/10600280231220379 . 267300725 .
  34. Humphrey C, Veve MP, Walker B, Shorman MA . Long-term vancomycin use had low risk of ototoxicity . PLOS ONE . 14 . 11 . e0224561 . 2019 . 31693679 . 6834250 . 10.1371/journal.pone.0224561 . 2019PLoSO..1424561H . free .
  35. Rybak LP, Ramkumar V, Mukherjea D . Ototoxicity of Non-aminoglycoside Antibiotics . Front Neurol . 12 . 652674 . 2021 . 33767665 . 7985331 . 10.3389/fneur.2021.652674 . free .
  36. Launay-Vacher V, Izzedine H, Mercadal L, Deray G . Clinical review: use of vancomycin in haemodialysis patients . Crit Care . 6 . 4 . 313–6 . August 2002 . 12225605 . 137311 . 10.1186/cc1516 . free .
  37. Azimi E, Reddy VB, Lerner EA . Brief communication: MRGPRX2, atopic dermatitis and red man syndrome . Itch . 2 . 1 . e5 . March 2017 . 28367504 . 5375112 . 10.1097/itx.0000000000000005 .
  38. Sivagnanam S, Deleu D . Red man syndrome . Critical Care . 7 . 2 . 119–20 . April 2003 . 12720556 . 270616 . 10.1186/cc1871 . free .
  39. Book: James W, Berger T, Elston D . 2005 . Andrews' Diseases of the Skin: Clinical Dermatology . 10th . 120–1. Saunders . 0-7216-2921-0 .
  40. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License .
  41. Cafaro A, Stella M, Mesini A, Castagnola E, Cangemi G, Mattioli F, Baiardi G . Dose optimization and target attainment of vancomycin in children . Clinical Biochemistry . 125 . 110728 . March 2024 . 38325652 . 10.1016/j.clinbiochem.2024.110728 . 267502279 .
  42. Van Bambeke F . Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy . Current Opinion in Investigational Drugs . 7 . 8 . 740–9 . August 2006 . 16955686 .
  43. Edlund C, Barkholt L, Olsson-Liljequist B, Nord CE . Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy . Clinical Infectious Diseases . 25 . 3 . 729–32 . September 1997 . 9314469 . 10.1086/513755 . free .
  44. Peláez T, Alcalá L, Alonso R, Rodríguez-Créixems M, García-Lechuz JM, Bouza E . Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin . Antimicrobial Agents and Chemotherapy . 46 . 6 . 1647–50 . June 2002 . 12019070 . 127235 . 10.1128/AAC.46.6.1647-1650.2002 .
  45. Waterer G, Lord J, Hofmann T, Jouhikainen T . Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus . Antimicrob Agents Chemother . 64 . 3 . February 2020 . 31964790 . 7038285 . 10.1128/AAC.01776-19 .
  46. Falagas ME, Trigkidis KK, Vardakas KZ . Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: A systematic review . Int J Antimicrob Agents . 45 . 3 . 221–33 . March 2015 . 25533880 . 10.1016/j.ijantimicag.2014.10.008 .
  47. Web site: Inhaled Vancomycin Monograph - Paediatric. Perth Children's Hospital (PCH). 19 July 2023. 14 March 2023. https://web.archive.org/web/20230314160643/https://pch.health.wa.gov.au/~/media/Files/Hospitals/PCH/General-documents/Health-professionals/ChAMP-Monographs/Vanomycin-Inhaled.pdf. live.
  48. Book: 10.1183/1393003.congress-2017.OA4655 . Eradication of MRSA ventilator-associated infection with inhaled vancomycin . Respiratory Infections . 2017 . Palmer LB, Smaldone GC . OA4655 .
  49. Web site: Is there literature describing the efficacy or safety of inhaled vancomycin to treat MRSA ventilator-associated tracheobronchitis? | Drug Information Group | University of Illinois Chicago. 19 July 2023. 19 July 2023. https://web.archive.org/web/20230719102710/https://dig.pharmacy.uic.edu/faqs/2020-2/march-2020-faqs/is-there-literature-describing-the-efficacy-or-safety-of-inhaled-vancomycin-to-treat-mrsa-ventilator-associated-tracheobronchitis/. live.
  50. Zarogoulidis P, Kioumis I, Lampaki S, Organtzis J, Porpodis K, Spyratos D, Pitsiou G, Petridis D, Pataka A, Huang H, Li Q, Yarmus L, Hohenforst-Schmidt W, Pezirkianidis N, Zarogoulidis K . Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol . Drug Des Devel Ther . 8 . 1065–72 . 2014 . 25143711 . 4136957 . 10.2147/DDDT.S66576 . free .
  51. Cantú TG, Yamanaka-Yuen NA, Lietman PS . Serum vancomycin concentrations: reappraisal of their clinical value . Clinical Infectious Diseases . 18 . 4 . 533–43 . April 1994 . 8038306 . 10.1093/clinids/18.4.533 .
  52. Moellering RC . Monitoring serum vancomycin levels: climbing the mountain because it is there? . Clinical Infectious Diseases . 18 . 4 . 544–6 . April 1994 . 8038307 . 10.1093/clinids/18.4.544 .
  53. Karam CM, McKinnon PS, Neuhauser MM, Rybak MJ . 24947921 . Outcome assessment of minimizing vancomycin monitoring and dosing adjustments . Pharmacotherapy . 19 . 3 . 257–66 . March 1999 . 10221365 . 10.1592/phco.19.4.257.30933 .
  54. Geraci JE . Vancomycin . Mayo Clinic Proceedings . 52 . 10 . 631–4 . October 1977 . 909314 .
  55. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, Dalovisio JR, Levine DP . Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists . American Journal of Health-System Pharmacy . 66 . 1 . 82–98 . January 2009 . 19106348 . 10.2146/ajhp080434 . 11692065 . 10.1.1.173.737 .
  56. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM . Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations . The Journal of Antimicrobial Chemotherapy . 63 . 5 . 1050–7 . May 2009 . 19299472 . 10.1093/jac/dkp085 . free . 15 September 2017 . 15 September 2017 . https://web.archive.org/web/20170915161446/http://strathprints.strath.ac.uk/13001/ . live .
  57. Izumisawa T, Kaneko T, Soma M, Imai M, Wakui N, Hasegawa H, Horino T, Takahashi N . Augmented Renal Clearance of Vancomycin in Hematologic Malignancy Patients . Biological & Pharmaceutical Bulletin . 42 . 12 . 2089–2094 . December 2019 . 31534058 . 10.1248/bpb.b19-00652 . free .
  58. Samel SA, Marahiel MA, Essen LO . How to tailor non-ribosomal peptide products--new clues about the structures and mechanisms of modifying enzymes . Molecular BioSystems . 4 . 5 . 387–93 . May 2008 . 18414736 . 10.1039/b717538h .
  59. Book: Dewick PM . Medicinal natural products: a biosynthetic approach . Wiley . New York . 2002 . 978-0-471-49641-0.
  60. van Wageningen AM, Kirkpatrick PN, Williams DH, Harris BR, Kershaw JK, Lennard NJ, Jones M, Jones SJ, Solenberg PJ . Sequencing and analysis of genes involved in the biosynthesis of a vancomycin group antibiotic . Chemistry & Biology . 5 . 3 . 155–62 . March 1998 . 9545426 . 10.1016/S1074-5521(98)90060-6 . free .
  61. Schlumbohm W, Stein T, Ullrich C, Vater J, Krause M, Marahiel MA, Kruft V, Wittmann-Liebold B . An active serine is involved in covalent substrate amino acid binding at each reaction center of gramicidin S synthetase . The Journal of Biological Chemistry . 266 . 34 . 23135–41 . December 1991 . 10.1016/S0021-9258(18)54473-2 . 1744112 . free . 3 June 2008 . 13 July 2024 . https://web.archive.org/web/20240713122158/https://www.jbc.org/article/S0021-9258(18)54473-2/fulltext . live .
  62. Stein T, Vater J, Kruft V, Otto A, Wittmann-Liebold B, Franke P, Panico M, McDowell R, Morris HR . The multiple carrier model of nonribosomal peptide biosynthesis at modular multienzymatic templates . The Journal of Biological Chemistry . 271 . 26 . 15428–35 . June 1996 . 8663196 . 10.1074/jbc.271.26.15428 . free .
  63. Kohli RM, Walsh CT, Burkart MD . 4380296 . Biomimetic synthesis and optimization of cyclic peptide antibiotics . Nature . 418 . 6898 . 658–61 . August 2002 . 12167866 . 10.1038/nature00907 . 2002Natur.418..658K .
  64. Puk O, Bischoff D, Kittel C, Pelzer S, Weist S, Stegmann E, Süssmuth RD, Wohlleben W . Biosynthesis of chloro-beta-hydroxytyrosine, a nonproteinogenic amino acid of the peptidic backbone of glycopeptide antibiotics . Journal of Bacteriology . 186 . 18 . 6093–100 . September 2004 . 15342578 . 515157 . 10.1128/JB.186.18.6093-6100.2004 .
  65. Schmartz PC, Zerbe K, Abou-Hadeed K, Robinson JA . Bis-chlorination of a hexapeptide-PCP conjugate by the halogenase involved in vancomycin biosynthesis . Organic & Biomolecular Chemistry . 12 . 30 . 5574–7 . August 2014 . 24756572 . 10.1039/C4OB00474D . free . 2 February 2024 . 2 February 2024 . https://web.archive.org/web/20240202143359/https://www.zora.uzh.ch/id/eprint/103226/1/manuscript.pdf . live .
  66. Haslinger K, Peschke M, Brieke C, Maximowitsch E, Cryle MJ . 4466657 . X-domain of peptide synthetases recruits oxygenases crucial for glycopeptide biosynthesis . Nature . 521 . 7550 . 105–9 . May 2015 . 25686610 . 10.1038/nature14141 . 2015Natur.521..105H . subscription . 23 June 2020 . 24 February 2021 . https://web.archive.org/web/20210224172657/https://www.nature.com/articles/nature14141 . live .
  67. Fu X, Albermann C, Jiang J, Liao J, Zhang C, Thorson JS . 2469387 . Antibiotic optimization via in vitro glycorandomization . Nature Biotechnology . 21 . 12 . 1467–9 . December 2003 . 14608364 . 10.1038/nbt909 .
  68. Fu X, Albermann C, Zhang C, Thorson JS . Diversifying vancomycin via chemoenzymatic strategies . Organic Letters . 7 . 8 . 1513–5 . April 2005 . 15816740 . 10.1021/ol0501626 .
  69. Peltier-Pain P, Marchillo K, Zhou M, Andes DR, Thorson JS . Natural product disaccharide engineering through tandem glycosyltransferase catalysis reversibility and neoglycosylation . Organic Letters . 14 . 19 . 5086–9 . October 2012 . 22984807 . 3489467 . 10.1021/ol3023374 .
  70. Evans DA, Wood MR, Trotter BW, Richardson TI, Barrow JC, Katz JL . Total Syntheses of Vancomycin and Eremomycin Aglycons . Angewandte Chemie . 37 . 19 . 2700–2704 . October 1998 . 29711601 . 10.1002/(SICI)1521-3773(19981016)37:19<2700::AID-ANIE2700>3.0.CO;2-P . free . doi .
  71. Book: Organic Synthesis Highlights . IV . 281–288 . Schmalz HG . 2008 . John Wiley & Sons . 38. Crossing the Finishing Line: Total Syntheses of the Vancomycin Aglycon . Herzner H, Rück-Braun K . 10.1002/9783527619979.ch38 . 978-3-527-61997-9 .
  72. Nicolaou KC, Mitchell HJ, Jain NF, Winssinger N, Hughes R, Bando T . 1999 . Total Synthesis of Vancomycin . Angew. Chem. Int. Ed. . 38 . 1–2. 240–244 . 10.1002/(SICI)1521-3773(19990115)38:1/2<240::AID-ANIE240>3.0.CO;2-5 .
  73. Winssinger N . Biography of Professor Nicolaou: a journey to the extremes of molecular complexity . The Journal of Antibiotics . 71 . 2 . 149–150 . February 2018 . 29375134 . 10.1038/ja.2017.144 . free . doi . Editorial .
  74. Next-Generation Total Synthesis of Vancomycin . Moore MJ, Qu S, Tan C, Cai Y, Mogi Y, Keith DJ, Boger DL . J. Am. Chem. Soc. . 202 . 142 . 37 . 16039–16050 . 10.1021/jacs.0c07433 . 32885969 . 13 July 2024 . 13 July 2024 . https://web.archive.org/web/20240713122125/https://doi.org/10.1021/jacs.0c07433.s001 . live . PDF . 7501256 .
  75. Crew PE, McNamara L, Waldron PE, McCulley L, Jones SC, Bersoff-Matcha SJ . Unusual Neisseria species as a cause of infection in patients taking eculizumab . J Infect . 78 . 2 . 113–118 . February 2019 . 30408494 . 7224403 . 10.1016/j.jinf.2018.10.015 .
  76. Mirrett S, Reller LB, Knapp JS . Neisseria gonorrhoeae strains inhibited by vancomycin in selective media and correlation with auxotype . J Clin Microbiol . 14 . 1 . 94–9 . July 1981 . 6790572 . 271907 . 10.1128/jcm.14.1.94-99.1981.
  77. Web site: Clinical Pharmacology . 10 September 2011 . 27 August 2021 . https://web.archive.org/web/20210827175717/http://www.clinicalpharmacology-ip.com/Forms/login.aspx?ReturnUrl=%2fForms%2fMonograph%2fmonograph.aspx%3fcpnum%3d638%26sec%3dmonmech&cpnum=638&sec=monmech . dead .
  78. Web site: vancomcin for plant cell culture. https://web.archive.org/web/20120504095939/http://www.toku-e.com/Upload/Products/index/Vancomycin%20HCl.pdf. dead. 4 May 2012.
  79. Pazuki A, Asghari J, Sohani MM, Pessarakli M, Aflaki F . 84495391 . 2014 . Effects of Some Organic Nitrogen Sources and Antibiotics on Callus Growth of Indica Rice Cultivars . Journal of Plant Nutrition . 38 . 8 . 1231–1240 . 10.1080/01904167.2014.983118 .
  80. Swenson JM, Facklam RR, Thornsberry C . Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species . Antimicrobial Agents and Chemotherapy . 34 . 4 . 543–9 . April 1990 . 2344161 . 171641 . 10.1128/AAC.34.4.543 .
  81. Hamilton-Miller JM, Shah S . Vancomycin susceptibility as an aid to the identification of lactobacilli . Letters in Applied Microbiology . 26 . 2 . 153–4 . February 1998 . 9569701 . 10.1046/j.1472-765X.1998.00297.x . 221924592 . free .
  82. Romney M, Cheung S, Montessori V . Erysipelothrix rhusiopathiae endocarditis and presumed osteomyelitis . The Canadian Journal of Infectious Diseases . 12 . 4 . 254–6 . July 2001 . 18159347 . 2094827 . 10.1155/2001/912086 . free .
  83. David V, Bozdogan B, Mainardi JL, Legrand R, Gutmann L, Leclercq R . Mechanism of intrinsic resistance to vancomycin in Clostridium innocuum NCIB 10674 . Journal of Bacteriology . 186 . 11 . 3415–22 . June 2004 . 15150227 . 415764 . 10.1128/JB.186.11.3415-3422.2004 .
  84. Kumar A, Augustine D, Sudhindran S, Kurian AM, Dinesh KR, Karim S, Philip R . Weissella confusa: a rare cause of vancomycin-resistant Gram-positive bacteraemia . Journal of Medical Microbiology . 60 . Pt 10 . 1539–1541 . October 2011 . 21596906 . 10.1099/jmm.0.027169-0 . free .
  85. Book: Quintiliani Jr R, Courvalin P . Mechanisms of Resistance to Antimicrobial Agents . Manual of Clinical Microbiology . Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH . ASM Press . Washington DC . 1995 . 6th . 1319 . 978-1-55581-086-3 . registration . https://archive.org/details/manualofclinical0000murr .
  86. Geraci JE, Wilson WR . Vancomycin therapy for infective endocarditis . Reviews of Infectious Diseases . 3 . suppl . S250-8 . 1981 . 7342289 . 10.1093/clinids/3.Supplement_2.S250 .
  87. Murray BE . Vancomycin-resistant enterococcal infections . The New England Journal of Medicine . 342 . 10 . 710–21 . March 2000 . 10706902 . 10.1056/NEJM200003093421007 . "The first reports of vancomycin-resistant enterococci (later classified as VanA type of resistance) involved strains of E. faecium that were resistant to vancomycin and teicoplanin (another glycopeptide) and that were isolated from patients in France and England in 1986. Vancomycin-resistant E. faecalis, subsequently classified as VanB type, was recovered from patients in Missouri in 1987." . subscription . 11 September 2022 . 11 September 2022 . https://web.archive.org/web/20220911090912/https://www.nejm.org/doi/10.1056/NEJM200003093421007 . live .
  88. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR . Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group . The New England Journal of Medicine . 340 . 7 . 493–501 . February 1999 . 10021469 . 10.1056/NEJM199902183400701 . free .
  89. McDonald LC, Killgore GE, Thompson A, Owens RC, Kazakova SV, Sambol SP, Johnson S, Gerding DN . 43628397 . An epidemic, toxin gene-variant strain of Clostridium difficile . The New England Journal of Medicine . 353 . 23 . 2433–41 . December 2005 . 16322603 . 10.1056/NEJMoa051590 . free .
  90. Acar J, Casewell M, Freeman J, Friis C, Goossens H . Avoparcin and virginiamycin as animal growth promoters: a plea for science in decision-making . Clinical Microbiology and Infection . 6 . 9 . 477–82 . September 2000 . 11168181 . 10.1046/j.1469-0691.2000.00128.x . free .
  91. Bager F, Madsen M, Christensen J, Aarestrup FM . Avoparcin used as a growth promoter is associated with the occurrence of vancomycin-resistant Enterococcus faecium on Danish poultry and pig farms . Preventive Veterinary Medicine . 31 . 1–2 . 95–112 . July 1997 . 9234429 . 10.1016/S0167-5877(96)01119-1 . 4958557 .
  92. Collignon PJ . Vancomycin-resistant enterococci and use of avoparcin in animal feed: is there a link? . The Medical Journal of Australia . 171 . 3 . 144–6 . August 1999 . 10474607 . 10.5694/j.1326-5377.1999.tb123568.x . 24378463 . Peter Collignon .
  93. Lauderdale TL, Shiau YR, Wang HY, Lai JF, Huang IW, Chen PC, Chen HY, Lai SS, Liu YF, Ho M . Effect of banning vancomycin analogue avoparcin on vancomycin-resistant enterococci in chicken farms in Taiwan . Environmental Microbiology . 9 . 3 . 819–23 . March 2007 . 17298380 . 10.1111/j.1462-2920.2006.01189.x . 2007EnvMi...9..819L . 20 April 2018 . 10 May 2019 . https://web.archive.org/web/20190510090150/http://ir.nhri.org.tw/bitstream/3990099045/1956/1/000244078500024.pdf . live .
  94. Pootoolal J, Neu J, Wright GD . Glycopeptide antibiotic resistance . Annual Review of Pharmacology and Toxicology . 42 . 381–408 . 2002 . 11807177 . 10.1146/annurev.pharmtox.42.091601.142813 .
  95. Xie J, Pierce JG, James RC, Okano A, Boger DL . A redesigned vancomycin engineered for dual D-Ala-D-ala And D-Ala-D-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteria . Journal of the American Chemical Society . 133 . 35 . 13946–9 . September 2011 . 21823662 . 3164945 . 10.1021/ja207142h . Dale L. Boger .
  96. Okano A, Isley NA, Boger DL . Peripheral modifications of [Ψ[CH<sub>2</sub>NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics . Proceedings of the National Academy of Sciences of the United States of America . 114 . 26 . E5052–E5061 . June 2017 . 28559345 . 5495262 . 10.1073/pnas.1704125114 . Dale L. Boger . free . 2017PNAS..114E5052O .
  97. Umstätter F, Domhan C, Hertlein T, Ohlsen K, Mühlberg E, Kleist C, Zimmermann S, Beijer B, Klika KD, Haberkorn U, Mier W, Uhl P . Vancomycin Resistance Is Overcome by Conjugation of Polycationic Peptides . Angewandte Chemie . 59 . 23 . 8823–8827 . June 2020 . 32190958 . 7323874 . 10.1002/anie.202002727 .
  98. Mier W, Umstätter F, Uhl P, Domhan C . Improved polypeptide coupled antibiotics. . EP . 3846854A2 . 4 September 2019 .
  99. Book: Shnayerson M, Plotkin M . 2003 . The Killers Within: The Deadly Rise of Drug-Resistant Bacteria . Back Bay Books . 978-0-316-73566-7 .
  100. Moellering RC . Vancomycin: a 50-year reassessment . Clinical Infectious Diseases . 42 . Suppl 1 . S3-4 . January 2006 . 16323117 . 10.1086/491708 . free .
  101. Griffith RS . Introduction to vancomycin . Reviews of Infectious Diseases . 3 . suppl . S200-4 . 1981 . 7043707 . 10.1093/clinids/3.Supplement_2.S200 .
  102. Web site: Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://web.archive.org/web/20160817081251/http://www.accessdata.fda.gov/scripts/cder/ob/docs/tempai.cfm. dead. 17 August 2016.
  103. Martin VT, Zhang Y, Wang Z, Liu QL, Yu B . A systematic review and meta-analysis comparing intrawound vancomycin powder and povidone iodine lavage in the prevention of periprosthetic joint infection of hip and knee arthroplasties . J Orthop Sci . 29 . 1 . 165–176 . January 2024 . 36470703 . 10.1016/j.jos.2022.11.013 . 254215681.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Vancomycin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.